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Overexpression of the Proteasome Subunits LMP2, LMP7, and
MECL-1, But Not PA28a/b, Enhances the Presentation of an
Immunodominant Lymphocytic Choriomeningitis Virus T Cell
Epitope1
Katrin Schwarz,* Maries van den Broek,† Susanne Kostka,‡ Regine Kraft,‡ Andrea Soza,2§
Gunter Schmidtke,* Peter-M. Kloetzel,§ and Marcus Groettrup3*
The proteasome is a large protease complex that generates most of the peptide ligands of MHC class I molecules either in their
final form or in the form of N-terminally extended precursors. Upon the stimulation of cells with IFN-g, three constitutively
expressed subunits of the 20S proteasome are replaced by the inducible subunits LMP2 (low-molecular mass polypeptide 2),
LMP7, and MECL-1 (multicatalytic endopeptidase complex-like-1) to form so-called immunoproteasomes. We show in this study
that overexpression of these three subunits in triple transfectants led to a marked enhancement in the H-2Ld-restricted presen-
tation of the immunodominant nonameric epitope NP118, which is derived from the nucleoprotein (NP) of lymphocytic chorio-
meningitis virus. Overexpression of the a and b subunits of the IFN-g-inducible proteasome regulator PA28, in contrast, did not
have a comparable effect. In vitro, immunoproteasomes as compared with constitutive proteasomes generated higher amounts of
11- and 12-mer fragments containing the NP118 epitope. These are likely to be cytosolic precursors of NP118, as a proline anchor
residue in the second position of NP118 may interfere with TAP-mediated transport of the nonameric epitope itself. In conclusion,
we provide evidence that up-regulation of the three inducible subunits, LMP2, LMP7, and MECL-1, can result in a marked
improvement of Ag presentation and that, depending on the epitope, PA28 and immunoproteasomes may differentially affect Ag
processing. The Journal of Immunology, 2000, 165: 768–778.
T he peptide ligands of MHC class I molecules have to ful-fill many criteria. To bind with high affinity to the pep-tide-binding groove of MHC class I molecules, they need
to be of a restricted length of 8 or 9 aa and must contain certain
amino acids as anchor residues (1). Moreover, they have to meet
the substrate requirements of the TAP, which transports MHC li-
gands or their precursors from the cytosol into the lumen of the
endoplasmic reticulum (ER)4 (2). The optimal length of peptides
for TAP-mediated transport lies between 8 and 12 aa, and both
murine MHC and TAP transporters select for peptides with hy-
drophobic C termini. Moreover, peptides that contain a proline in
positions 2 are inefficiently transported by human or mouse TAPs
(2, 3). As the class I molecules H-2Ld in the mouse or HLA-B35
and HLA-B53 in the human require proline at position 2, this
implies that their peptide ligands are probably produced in the
cytoplasm as precursors of at least 10 aa in size. It has been shown
that the C termini of MHC ligands are normally generated by pro-
teases in the cytoplasm, while the final N termini can still be generated
in the ER lumen by to date unidentified amino peptidases (4, 5).
Experiments employing inhibitors of the proteasome have
meanwhile shown that it is the proteasome system (6) that gener-
ates most of the class I ligands and their precursors (7–10). This
notion has been further corroborated by the discovery of two IFN-
g-inducible proteasome subunits named LMP2 and LMP7, which
are encoded in the MHC class II locus. Upon their transcriptional
induction, LMP2 and LMP7 replace two constitutive b-type sub-
units designated d and MB-1, respectively, in newly assembled
20S proteasomes. The exchange of these proteasome subunits was
shown to alter the cleavage specificity of the 20S proteasome in
vitro. Replacement of the subunit d by LMP2, for instance, dra-
matically reduced the proteasomal cleavages C terminal of glu-
tamic acid, while the exchange of LMP7 for MB-1 was found to
increase the cleavage C terminal of hydrophobic residues in one
(11), but not in other studies (12–14). The in vivo effects of LMP2
and LMP7 were analyzed in gene-targeted mice and mutant cell
lines. LMP7-deficient mice displayed a slight reduction of MHC
class I molecules on lymphocytes and macrophages and a reduced
ability to present the HY male Ag (15). The reduction in class I
expression could be rescued by administration of exogenous pep-
tides, indicating that the defect was due to a lack of appropriate
peptide ligands. LMP2-deficient mice, in contrast, were not re-
duced in class I cell surface expression, but had a slightly reduced
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level of CD81 T lymphocytes and generated fewer CTL precursors
to an influenza NP epitope, while the response to Sendai virus was
normal (16). LMP2 and LMP7 double-deficient lymphoblastoid
cell lines showed no significant reduction in class I cell surface
expression (17, 18) and no apparent defect in the class I-restricted
presentation of several virus-derived T cell epitopes (19, 20). Only
in a mouse cell line selectively deficient for LMP2 it could be
shown that this subunit was required for presentation of two
epitopes of influenza hemagglutinin (21). Taken together, the im-
pact of LMP2 and LMP7 on Ag processing and presentation was
evident for certain epitopes, but not very prominent for the bulk
production of MHC class I ligands.
Recently, a third pair of subunit exchanges in the 20S protea-
some has been discovered. The subunit MECL-1, which, in con-
trast to LMP2 and LMP7, is not encoded in the MHC, is inducible
by IFN-g and replaces a subunit that was designated Z in the
human and MC14 or LMP9 in the mouse (22–24). The function of
MECL-1 in Ag presentation has not been investigated to date, and
cell lines or mice that are deficient for MECL-1 are not yet avail-
able. Interestingly, the incorporation of MECL-1 into the 20S pro-
teasome is strictly dependent on the subunit LMP2 (25) and is
accelerated in the presence of LMP7 (26), suggesting that these
subunits are preferentially coincorporated, leading to the formation
of so-called immunoproteasomes. As the constitutively expressed
subunits d, MB-1, and MC14 bear the three putative active centers
of the proteasome, it appears that all three subunits have an IFN-
g-inducible homologue and are amenable to modulation during the
immune response.
The 20S proteasome must be viewed as a proteolytic core com-
plex that needs to associate with regulatory complexes that control
the cleavage activity of the proteasome and the access of substrates
to the lumen of the 20S proteasome. The PA700 complex (or 19S
regulator) consists of at least 17 different subunits, and is thought
to be required for the binding and unfolding of ubiquitinated pro-
teins (6). The PA28 complex (or 11S regulator), in contrast, is
constituted from two different subunits, PA28a and PA28b, which
both are inducible by IFN-g (27). They form rings of seven sub-
units with about equal stoichiometric amounts of a and b, which
bind to the 20S proteasome (28–30). Both the PA28a and b sub-
units have been shown to enhance peptide hydrolysis by the 20S
proteasome, but the respective functional contributions of a and b
are still elusive (31–33). With respect to PA28 function, we pro-
posed that it is involved in Ag processing, as overexpression of the
PA28a subunit markedly enhanced the Ag presentation of two
different virus-derived epitopes (34). Moreover, PA28 accelerated
the processing of nonameric MHC ligands from polypeptide pre-
cursors by the 20S proteasome in vitro (35). Mechanistically, it
was proposed that PA28 induces the proteasome to perform dual
cleavages that immediately would liberate fragments of the appro-
priate size from polypeptides precursors rather than performing
consecutive cleavages (35, 36). Although these experimental find-
ings obtained in several models systems support the proposed role
for PA28 in Ag processing, it remains to be shown whether all T
cell epitopes similarly benefit from PA28 expression.
In this work, we aimed at dissecting the effects of IFN-g on Ag
processing by the proteasome system by the means of overexpress-
ing either mouse PA28a and b or the subunits LMP2, LMP7, and
MECL-1 in double and triple transfectants of mouse fibroblasts,
respectively. As a model system for Ag presentation, we chose the
infection of BALB/c-derived fibroblast lines with the lymphocytic
choriomeningitis virus (LCMV). The cytotoxic immune response
to LCMV is essential for elimination of the virus from infected
mice. In BALB/c mice, this response is strongly dominated by
CTLs specific for the H-2Ld-restricted nonameric epitope NP118
(37), which consists of residues 118–126 of the LCMV-NP and is
generated in a proteasome-dependent manner (38). We report in
this study that the presentation of NP118 is markedly enhanced
through LMP2/LMP7/MECL-1 coexpression, and that the putative
11- and 12-mer precursors of this epitope are produced in vitro by
immunoproteasomes much more efficiently as compared with con-
stitutive proteasomes. Overexpression of PA28a/b, in contrast,
had little effect on Ag presentation in this system. Taken together,
our data demonstrate that the concerted expression of the IFN-g-
inducible proteasome subunits LMP2, LMP7, and MECL-1 may
greatly enhance the efficiency of the intracellular T cell epitope
production.
Materials and Methods
Mice and LCM virus
BALB/c mice (H-2d) were purchased from the Institut fu¨r Labortierkunde,
Tierspital Zu¨rich (Zu¨rich, Switzerland) and kept in a specific pathogen-free
environment. LCMV-WE strain was originally obtained from F. Lehmann-
Grube (Hamburg, Germany) (39). LCMV was propagated in the L929
fibroblast line, and viral stocks were kept at 270°C.
Synthetic peptides
The synthetic peptides were purchased from Echaz microcollections (Tu¨-
bingen, Germany). The 25-mer encompassing LCMV-WE NP residues
108–132 KLKAKIMRTERPQASGVYMGNLTAQ contained the immu-
nodominant 9-mer epitope (NP118–126), which is presented by H-2Ld.
Antibodies
For Western blot analysis, rabbit polyclonal Abs recognizing mouse LMP2
(26), LMP7 (Affinity, Mamhead, U.K.), and MECL1 (25) as well as the
PA28a and PA28b subunits (40) were used. The secondary Ab was a goat
anti-rabbit Ig HRP conjugate (Dako, Zug, Switzerland). For immunopre-
cipitation of the proteasome, a rabbit anti-mouse proteasome antiserum was
used. The LCMV-NP was immunoprecipitated using the rat mAb VL4
(41). For surface staining of the H-2Ld, H-2Kd, and H-2Dd molecules, the
mAbs 28-14-81, 15-5-5S, and 19/191 were used and the LCMV-glycop-
rotein staining was performed with the mouse mAb KL 25 (42), followed
by a FITC-conjugated sheep anti-mouse Ig (Silenus, Victoria, Australia).
The intracellular staining of the LCMV-NP was performed using mAb
VL4, followed by a PE-conjugated rabbit anti-rat IgG (Serotec, Oxford,
U.K.).
Cell lines
The B8 clone was obtained from Dr. U. Koszinowski (Munich, Germany),
and had been generated from the BALB/c-derived fibroblast cell line C4 by
cotrancfection with the IE1/pp89 gene of the mouse CMV and a neomycin-
resistance gene (13). B8 cells were grown in complete IMDM (10% FCS,
2 mM L-glutamine, 100 U/ml penicillin/streptomycin) supplemented with
250 mg/ml G418. The stimulation of B8 cells with IFN-g was always done
for 2 days with 20 U/ml mouse rIFN-g (Life Technologies, Basel, Swit-
zerland). Triple transfection of B8 cells with the BALB/c-derived LMP2,
LMP7, and MECL1 cDNAs yielded the clones B27 M2 (25), B27 M6, and
B27 M9. Transfection of the MECL-1 transfectant BME13 (25) with a
LMP2 expression vector yielded the cell line B2 M1. Double transfection
of B8 cells with the cDNA of mouse PA28a and b (40) generated the
clones BPab2 and BPab13. These cells were cultured in selection medium
consisting of complete IMDM supplemented with 2.5 mg/ml puromycin
(Sigma, Buchs, Switzerland), 400 mg/ml hygromycin B (Roche, Basel,
Switzerland), and 250 mg/ml G418 (Life Technologies). T2-Ld is the TAP-
deficient human lymphoblastoid line T2 cell line (43) transfected with
H-2Ld.
CTL lines and T cell hybridoma
CTL lines recognizing the LCMV-NP epitope NP118 were generated from
spleen cell suspensions of LCMV memory mice that had been infected i.v.
with 200 PFU LCMV-WE at least 1 mo before. Splenocytes were plated in
complete IMDM supplemented with 5 3 1025 M 2-ME and 10% rat Con
A supernatant. Cells were restimulated every 7–10 days with NP118 pep-
tide-loaded and irradiated (80 Gy) T2-Ld cells at a ratio of CTL to APC of
5:1. Loading with synthetic peptides was for 1 h at room temperature with
1027 M of peptide. Generally, the CTL line was found to be exclusively
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specific for NP118/H-2Ld after three rounds of restimulation. For the ex
vivo CTL assay, mice were infected i.v. with 200 PFU LCMV-WE, and
after 8 days, the mice were sacrificed and a spleen cell suspension was
prepared for immediate use as effector cells in a standard chromium release
assay. The NP-118-specific hybridoma clone HNP-118 resulted from a
fusion of an LCMV NP118-specific CTL line with the TCR-deficient lym-
phoma BWZ36.1 (44) expressing CD8a and a lacZ reporter construct un-
der the control of the IL-2 promotor/enhancer (38). These cells were grown
in complete IMDM/hypoxanthine, aminopterin, thymidine (HAT; Sigma)
supplemented with 0.5 mg/ml hygromycin B.
Generation of rVV-NP118
We cloned the synthetic DNA sequence encoding the nonameric NP118–
126 epitope plus one additional methionine at the N terminus (MRPQAS-
GVYM) into the vaccinia vector pSC11.3OR2 (45). The plasmid DNA was
used to cotransfect thymidine kinase-negative 143B fibroblasts (American
Type Culture Collection (ATCC), Manassas, VA) after their infection with
wild-type vaccinia virus. Successful homologous recombination of the vac-
cinia vector with the vaccinia virus was assessed by selection for 5-bromo-
29-deoxyuridine-resistant, b-galactosidase-expressing virus plaques.
Plaques were selected and replaqued three times until one isolated plaque
was chosen for amplification on BS-C-40 (ATCC) cells.
Purification of 20S proteasome
The lysis, purification, and quantitation of the 20S proteasome from B8
cells were performed exactly as described (13).
Metabolic labeling and immunoprecipitation
Cells grown to confluence were starved in cysteine/methionine-free RPMI
1640, 10% dialyzed FCS for 1 h at 37°C and labeled with 0.2 mCi/ml
Tran35S label (ICN, Eschwege, Germany) for the indicated time. Labeling
medium was removed and cells were washed with PBS, harvested, and
lysed for 30 min at 4°C in 50 mM Tris/HCl, pH 8, 150 mM NaCl, 1 mM
EDTA, 0.5% Nonidet P-40, 0.75 mM aprotinin, 10 mM leupeptin, 2.8 mM
pepstatin, and 0.85 mM PMSF. The postnuclear lysates were counted for
35S incorporation, and equal aliquots were used for immunoprecipitation.
The lysate was precleared for 1 h at 4°C with preimmune serum coupled to
protein G-Sepharose CL-4B (Pharmacia, Uppsala, Sweden), followed by
immunoprecipitation with the indicated Ab bound to protein G-Sepharose
for 3 h at 4°C. The precipitates were washed with PBS, pH 7.5, 0.1% Triton
X-100, and separated on IEF and/or SDS-PAGE (performed as described
in Ref. 23). The proteins were visualized by autoradiography on x-ray films
or by using a BAS 1500 radioimager (Fuji, Tokyo, Japan).
Western blot analysis
Cells were lysed in 50 mM Tris/HCl, pH 7.5, 5 mM MgCl2, 1 mM EDTA,
0.5% Triton X-100, 0.75 mM aprotinin, 10 mM leupeptin, 2.8 mM pepsta-
tin, and 0.85 mM PMSF for 30 min at 4°C. The postnuclear supernatant
was quantified by OD, and aliquots of 130 mg protein were applied to a
12% SDS-PAGE. The proteins were blotted onto nitrocellulose membrane
(Schleicher und Schuell, Dassel, Germany), blocked with PBS/10% horse
serum/5% (w/v) low fat dry milk/0.4% Tween-20, and agitated overnight
at 4°C with the indicated Ab in PBS/2% low fat dry milk/0.1% Tween-20.
The blots were washed and incubated for 1 h with the HRP-conjugated
secondary Ab. After extensive washing with PBS/0.2% Tween-20, proteins
were visualized on x-ray films by enhanced chemiluminescence.
Proteasomal fragmentation of polypeptides and analysis of
peptide products
A total of 80 mg of a synthetic 25-mer peptide derived from the sequence
of the LCMV-NP (NP108–132) was incubated with 4 mg purified 20S
proteasome in a total volume of 1200 ml of digestion buffer (30 mM Tris/
HCl, pH 7.5, 10 mM KCl, 2 mM DTT) at 37°C. At indicated time points,
aliquots of 300 ml were removed and frozen to stop the reaction. These
cleavage products were separated on a mRPC C2/C18 SC 2.1/10 reverse-
phase column using a SMART System (Pharmacia). Eluent A, 0.1% trif-
luoroacetic acid (TFA); eluent B, 70% acetonitrile 1 0.1% TFA. Gradient
10–30% B in 55 min, flow rate 100 ml/min. Peak fractions were collected,
vacuum dried, and resolved in 60% acetonitrile, 0.1% TFA. For the iden-
tification of peptides, the samples were coprecipitated with a matrix of
a-cyano-4-hydroxycinnamic acid in acetone and analyzed by MALDI-MS
FIGURE 1. Two-dimensional IEF/PAGE analysis of
proteasomes immunoprecipitated from three different
LMP2/LMP7/MECL-1 triple transfectants (B27 M2,
B27 M6, and B27 M9) as well as the parental B8 line
grown in the presence and absence of IFN-g. The cells
were labeled with [35S]methionine/cysteine for 4 h and
then grown for 5 h in chase medium to allow full mat-
uration of 20S proteasomes. The positions of the house-
keeping subunits d and MC14 and the IFN-g-inducible
subunits LMP2 and MECL1 are indicated on the
autoradiographies.
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(VG-TofSpec; Fison Instruments, Manchester, U.K.). For microsequence
analyses of the HPLC-separated peptide samples, a Procise protein se-
quencer system (Applied Biosystems, Foster City, CA) was used.
Cytolytic assays
Target cells (B8 fibroblasts and transfecants thereof) were infected either
for 24 h with LCMV-WE at a multiplicity of infection of 0.01 or for 1 h
with rVV-NP118 with a multiplicity of infection of 3. One million cells
were labeled in 200 ml with 100 mCi Na251CrO4 for 1 h at 37°C before
washing and incubation of 104 cells/well in a 96-well plate with effector
CTL at indicated E:T ratios at 37°C. Chromium release was measured after
4 h in 70 ml of culture supernatant. For determining the spontaneous re-
lease, the supernatant of target cells without adding effector CTL was mea-
sured. The total release was determined by adding 0.1% Nonidet P-40
(final concentration) to labeled targets. Specific lysis was calculated as
(experimental release 2 spontaneous release)/(total release 2 spontaneous
release) 3 100%. All samples were measured in triplicates.
lacZ assay
The LCMV-NP118-specific hybridoma clone HNP-118 was cocultured
overnight with 5 3 104 LCMV-infected target cells in 96-well plates at an
E:T ratio of 10:1, 5:1, and 1:1. The cultures were washed once with PBS
and lysed by addition of 100 ml of Z buffer (0.15 mM chlorophenol red
b-galactoside (CPRG; Roche), 100 mM 2-ME, 9 mM MgCl2, 0.125%
Nonidet P-40 in PBS). After 4 h of incubation at 37°C, the absorbance at
570 nm (reference wavelength at 620 nm) was read using a SpectraFluor
Plus plate reader (Tecan, Gro¨ding, Austria).
Viability assay
A total of 20 ml Cell Titer 96 AQueous One Solution Reagent was added
to 5 3 104 cells in 100 ml medium in 96-well plates. The plates were
incubated for 1 h at 37°C before the absorbance was recorded at 450 nm
using the SpectraFluor Plus plate reader.
Flow cytometry
For surface staining, aliquots of 4 3 105 cells in PBS 1 2% FCS were
incubated for 15 min in a round-bottom 96-well plate on ice with the
indicated Ab, washed three times, and subsequently stained by FITC-con-
jugated secondary Ab. The LCMV-NP was detected by intracellular stain-
ing. In brief, aliquots of LCMV-infected cells were permeabilized with
0.1% saponin (Sigma) in PBS 1 2% FCS for 10 min, and the staining was
performed in this buffer until completion. The NP was stained for 30 min
with the VL4 Ab, washed twice, and subsequently stained by PE-conju-
gated Ab for an additional 30 min. After two washing steps, the staining
was analyzed on a FACScan flow cytometer (Becton Dickinson, Mountain
View, CA).
Results
The stimulation of cells with IFN-g was estimated to induce up to
400 genes, many of which can be expected to influence the MHC
class I-restricted Ag presentation pathway (46). In this work, we
wanted to separately investigate how an incorporation of the sub-
units LMP2, LMP7, and MECL-1 into the proteasome as it occurs
subsequent to IFN-g stimulation would affect Ag processing and com-
pare it with the effect of PA28 up-regulation. To this end, we created
transfectants overexpressing either the a and b subunits of PA28 or
the three IFN-g-inducible subunits of the immunoproteasome.
Characterization of transfectants expressing LMP2/LMP7/
MECL-1 and PA28a/b
For the generation of stable transfectants, we chose the mouse
fibroblast line B8, which endogenously expresses little LMP2,
LMP7, and MECL-1. Expression constructs encoding these three
subunits were transfected, and after isolation of drug-resistant
cells, three different clones named B27 M2, B27 M6, and B27 M9,
which according to Northern analysis strongly overexpressed the
respective mRNAs (data not shown), were chosen for further char-
acterization. The 20S proteasomes of these transfectants and, for
FIGURE 2. Western blot analysis of the expression of LMP2, LMP7,
MECL-1, PA28a, and PA28b. Total lysates of untreated or IFN-g-stimu-
lated B8 cells; the LMP2/LMP7/MECL-1 triple transfectants B27 M2, B27
M6, and B27 M9; as well as the PA28a/b transfectants BPab2 and
BPab13 were blotted and probed with polyclonal antisera of the respective
specificities. The relative molecular masses (indicated on the left) corre-
sponded well to the predicted Mr of the respective murine proteins, as
indicated.
FIGURE 3. Flow-cytometric analysis of MHC class I cell surface ex-
pression of untreated or IFN-g-stimulated B8 cells; the LMP2/LMP7/
MECL-1 triple transfectants B27 M2, B27 M6, and B27 M9; as well as the
PA28a/b transfectants BPab2 and BPab13. Cells were stained for the
H-2Kd, H-2Ld, and H-2Dd class I molecules, as indicated, followed by a
FITC-conjugated sheep anti-mouse Ig secondary Ab (filled curves). The
open curves are stainings with the secondary Ab alone.
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comparison, of IFN-g-stimulated and unstimulated B8 cells were
immunoprecipitated under stringent conditions, and the composi-
tion of proteasome subunits was analyzed on two-dimensional
IEF/PAGE. As shown on autoradiographies in Fig. 1, the three
triple transfectants expressed LMP2 and MECL-1 in amounts that
were comparable with those of IFN-g-stimulated B8 cells, while in
untreated B8 cells these subunits were not detectable. The consti-
tutively expressed proteasome subunits d and MC14 were replaced
to a large extent by LMP2 and MECL-1, respectively, in the triple
transfectants and in IFN-g-treated cells in accordance with previ-
ous reports (22–24). Unfortunately, the LMP7 subunit has a basic
isoelectric point, and hence migrates out of the IEF gel of our
two-dimensional electrophoretic system. Therefore, we examined
the expression level of LMP7 as well as of LMP2 and MECL-1 in
Western analysis. As shown in Fig. 2, the inducible subunits are
found in the triple transfectants in similar amounts as in IFN-g-
treated B8 cells, while in unstimulated B8 cells neither LMP2 nor
MECL-1 and only little LMP7 were detected. Thus, the Western
results are congruent with the immunoprecipitation analysis (Fig.
1) and a previous examination of purified 20S proteasomes from
the triple transfectant B27 M2 and IFN-g-treated and untreated B8
cells on Coomassie-stained nonequilibrium pH-gradient gel elec-
trophoresis (NEPHGE)/PAGE two-dimensional gels (13, 23, 25).
From these gels, it was apparent that the exchange of LMP7 for
FIGURE 4. Comparison of the H-2Ld-restricted presentation of the LCMV-NP118 epitope by LCMV or rVV-NP118-infected cell lines transfected with
LMP2/LMP7/MECL-1 or PA28a/b in cytolytic assays. A, Cytolytic assay with NP118/H-2Ld-specific CTLs as effectors obtained from LCMV-infected
BALB/c mice by repeated in vitro restimulation with the NP118 peptide. Target cells were IFN-g-stimulated or unstimulated B8 cells; the LMP2/LMP7/
MECL-1 triple transfectants B27 M2, B27 M6, and B27 M9; as well as the PA28a/b transfectants BPab2 and BPab13. B, Ex vivo cytolytic assay using
spleen cells from BALB/c mice 8 days after infection with LCMV as effectors and targets, as in A. The ex vivo cytotoxic response in mice of the H-2d
haplotype to LCMV is known to be directed predominantly to the NP118 epitope. C, NP118-specific cytolysis of transfectants after infection with
rVV-NP118 encoding the NP118 epitope as a minigene. As negative control, B8 cells were infected with rVV-glycoprotein encoding the LCMV glyco-
protein. D, Cytolytic assay comparing NP118 presentation in LCMV-infected B8 recipient cells and clones transfected with the empty expression vector
(B8 vector 1, B8 vector 2), or with expression constructs encoding LMP2/LMP7/MECL-1 (B27 M2, B27 M6) or LMP2/MECL-1 (B2 M1) at an E:T ratio
of 10. Data represent the means of three replicate cultures; representative results from three independent experiments are shown.
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MB-1 was complete in the B27 M2 transfectant and B8 cells after
treatment with IFN-g for 3 days.
To compare the joint effects of LMP2, LMP7, and MECL-1 on
Ag presentation with that of PA28, we have generated double
transfectants overexpressing both the PA28a and b subunits. Two
clones designated BPab2 and BPab13 were chosen for further
characterization, as they strongly expressed both mRNAs in North-
ern analysis (not shown). Western analysis revealed that the
PA28a expression in these clones was comparable with IFN-g-
treated B8 cells and exceeded that of the low basal expression in
B8 recipient cells by a factor of about 3 (Fig. 2). The PA28b
protein was barely detectable in B8 cells, but prominently ex-
pressed in the BPab2 and BPab13 transfectants to an amount that
was equal or even higher than found in IFN-g-treated cells.
The overexpression of LMP2, LMP7, and MECL-1 or PA28a
and b does not alter class I cell surface expression
A potential function that is discussed both for the inducible sub-
units of the immunoproteasome and for PA28 is an enhancement
in the production of appropriate peptide ligands for class I presen-
tation. As MHC ligands are required for the stabilization and cell
surface transport of class I molecules, we investigated whether
their surface expression would be altered by LMP2/LMP7/
MECL-1 or PA28a/b overexpression. The B8 fibroblast line was
originally derived from a BALB/c mouse, and hence expresses the
MHC class I molecules H-2Ld, H-2Dd, and H-2Kd. A flow-cyto-
metric analysis revealed that neither the joint overexpression of
LMP2, LMP7, and MECL-1 nor of PA28a and b had a significant
effect on the surface expression of these class I molecules (Fig. 3).
Only the treatment of B8 cells with IFN-g resulted in an about
10-fold increase in class I surface expression. This result indicates
that if there is a change in Ag processing in the transfectants, this
cannot be attributed to a general alteration of MHC class I cell
surface expression.
The coexpression of LMP2, LMP7, and MECL-1 enhanced the
Ag presentation of an LCMV-NP epitope
The cytotoxic immune response to LCMV in mice of the H-2d
haplotype is predominantly directed against a H-2Ld-restricted
peptide epitope called NP118, which is constituted from the
LCMV-NP residues 118–126 (37). We decided to compare the
presentation of the NP118 epitope of LCMV-infected B8 cells
with that of LMP2/LMP7/MECL-1 and PA28a/b transfectants.
The cells were LCMV infected and used after 24 h as targets in a
cytolytic chromium release assay employing NP118/H-2Ld-spe-
cific CTLs as effectors. Remarkably, the LMP2/LMP7/MECL-1
triple transfectants showed a strong enhancement of cytolysis by
NP118-specific T cells when compared with parental B8 cells. As
can be seen in Fig. 4A, two to three times more LMP2/LMP7/
MECL-1-transfected cells compared with B8 cells were lysed by
the same effectors in several independent experiments, and this
difference could not be overcome by increasing the amounts of
effector cells to higher E:T ratios. Interestingly, the PA28a/b dou-
ble transfectants were lysed by NP118-specific CTLs to a similar
extent as untransfected B8 cells. The latter finding differs from
previous results obtained with PA28a single transfectants of B8
using CTLs specific for the influenza NP or the mouse CMV im-
mediate early protein pp89 (34), suggesting that the effects of
PA28 may not promote Ag presentation in different systems to the
same degree.
To confirm and extend our findings in another experimental set-
ting, we repeated this test as an ex vivo cytolytic assay using the
same cells as well as IFN-g-stimulated B8 cells as targets and
freshly isolated CTLs from LCMV-infected mice as effectors. As
it has been shown that in a primary H-2d-restricted immune re-
sponse to LCMV no epitopes other than NP118 significantly con-
tribute to cytolysis (47), it is safe to assume that the results ob-
tained in a polyclonal ex vivo response reflect the recognition of
NP118. Also, in this set up, the LCMV-infected LMP2/LMP7/
MECL-1 triple transfectants were recognized much better than B8
cells or the PA28a/b transfectants (Fig. 4B). Moreover, we found
that the treatment of B8 cells with IFN-g enhanced the cytolysis to
FIGURE 5. Quantification of LCMV-NP in different infected target
cells used for cytolytic assay. A, Immunoprecipitation of the LCMV-NP
from LCMV-infected target cells as prepared for the ex vivo cytolytic
assay shown in Fig. 4B. Cells were labeled with [35S]methionine/cysteine
for 2 h, and LCMV-NP was immunoprecipitated with mAb VL4. Shown is
an autoradiography of 15% SDS-PAGE; the position of Mr markers is
indicated on the left, and the position of LCMV-NP on the right. B, Flow-
cytometric quantitation of NP expression in LCMV-infected target cells
24 h after they were used for ex vivo cytolytic assay. Infected cells were
stained intracellularly with the LCMV-NP-specific Ab VL4, followed by a
PE-conjugated secondary Ab (filled curves); the open curves represent con-
trol stainings with the secondary Ab alone.
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a similar degree as the overexpression of LMP2, LMP7, and
MECL-1, suggesting that immunoproteasomes contribute consid-
erably to this enhancement. To confirm that the elevated NP118
presentation in LMP2/LMP7/MECL-1 triple transfectants was due
to an enhancement in epitope generation and not to unrelated de-
fects in the control cell lines, we generated the vaccinia recombi-
nant rVV-NP118 encoding the nonameric NP118 epitope as a
minigene. Infection with rVV-NP118 led to a high lysis by NP118-
specific CTLs, which was equal for the B8 recipient and the trans-
fectants, indicating that the enhanced NP118 presentation in
LCMV-infected LMP2/LMP7/MECL-1 triple transfectants was
due to a better efficiency in Ag processing (Fig. 4C). As LMP2 and
MECL-1 on the one hand and LMP7 on the other hand can incor-
porate into the 20S proteasome independently, we decided to in-
vestigate how an LCMV-infected LMP2/MECL-1 double trans-
fectant of B8 would present the NP118 epitope. As shown in Fig.
4D, also in the LMP2/MECL-1 double transfectant B2 M1, the
NP118 epitope was presented at a higher level, suggesting that
expression of LMP2 and MECL-1 is sufficient to achieve this en-
hancement. To ensure that the observed effects were not due to
clonal variation or transfection artefacts, we tested two B8 clones
that were transfected with the empty expression vector in the same
experiment, and they, as expected, presented the NP118 epitope at
the same level as the B8 recipient cells (Fig. 4D).
To exclude that the increase in presentation of NP118 in the
triple transfectants was due to higher LCMV replication and NP
synthesis in these cells, we immunoprecipitated the NP from the
same batch of cells that were used as target cells in the ex vivo
cytolytic assays (Fig. 4B). As shown in Fig. 5A, the NP content
was not significantly different in the LMP2/LMP7/MECL-1 triple
transfectants, the PA28a/b double transfectants, or B8 cells in the
presence or absence of IFN-g. This result was further confirmed by
flow-cytometric analysis, which revealed identical levels of
LCMV-NP expression in LCMV-infected B8 cells and the trans-
fectants (Fig. 5B). Thus, we conclude that the improved recogni-
tion of LMP2/LMP7/MECL-1 triple transfectants must be due to a
greater efficiency in the intracellular generation of the NP118
epitope rather than a higher level of NP synthesis in these cells.
Recently, we have produced a T cell hybridoma designated
HNP-118, which is specific for the NP118 epitope presented on
H-2Ld and which contains a b-galactosidase reporter gene under
the IL-2 promotor/enhancer. The recognition of H-2Ld/NP118 and
activation of the hybridoma can thus be quantitated in a chromo-
genic assay of b-galactosidase activity. Also, in this assay, the
LMP2/LMP7/MECL-1 triple transfectants were recognized much
better compared with parental B8 cells (Fig. 6A), although the cell
number and viability (Fig. 6B) as well as LCMV-NP expression
(data not shown) were identical among stimulators.
Taken together, it appears from three independent experimental
systems that the incorporation of LMP2, LMP7, and MECL-1 into
the proteasome in vivo markedly enhanced the production of
NP118 epitopes and/or their precursors. As the incorporation of the
IFN-g-inducible subunits is believed to alter the peptide process-
ing of the 20S proteasome, we decided to investigate in vitro
whether evidence for altered processing can be obtained in this
model and whether these changes are consistent with the observed
in vivo effects.
Immunoproteasomes greatly favor the in vitro production of
putative cytosolic precursors of the NP118 epitope
We purified 20S proteasomes both from B8 cells and from the
triple transfectant B27 M2 and monitored the fragmentation of a
synthetic 25-mer polypeptide from the sequence of LCMV-NP that
contained the nonameric NP118 epitope. After several time peri-
ods, aliquots were removed from the proteolytic reaction and the
fragments were separated by reversed phase HPLC (Fig. 7) and
identified by MALDI-MS and automated Edman degradation. It is
apparent that the same kind of fragments were produced by con-
stitutive proteasomes from B8 cells and immunoproteasomes iso-
lated from B27 M2 cells. However, although the kinetics of 25-
mer consumption was comparable, the quantity of the respective
peptide fragments produced differed markedly between the two
proteasome populations. These fragments accumulated over the
time of the digest, indicating that these differences in fragment
quantity were already apparent at early time points of the cleavage
reaction when the 25-mer substrate was still in excess.
To assign and quantify fragments that could be especially rel-
evant for the generation of the NP118 epitope, Edman degradation
was performed. Remarkably, the amounts of 11-and 12-mer frag-
ments that contained the NP118 epitope (Fig. 8) were produced by
immunoproteasomes in about 6- and 3-fold higher amounts, re-
spectively. A 10-mer containing NP118 was produced in double
amounts by constitutive proteasomes, but it was not a prominent
fragment in either of the reactions. Also, the NP118 nonamer
FIGURE 6. A, The stimulation of a LCMV-NP118-specific hybridoma through various LCMV-infected cells as monitored in a lacZ chromogenic assay.
Stimulator cells were untreated or IFN-g-stimulated B8 cells and the LMP2/LMP7/MECL-1 triple transfectants B27 M2, B27 M6, and B27 M9. Stimulator
cells were infected 24 h before they were incubated with hybridomas at a hybridoma to stimulator cell ratio of 5:1. The absorption of the generated dye
at 570 nm is plotted for each stimulator cell. All LCMV-infected stimulator cells expressed comparable levels of LCMV-NP, as determined by immu-
noprecipitation (not shown). One representative experiment of three is shown; data represent the mean of triplicate values. B, Viability staining to normalize
for the number and viability of stimulator cells. The absorption at 450 nm of a dye produced in viable stimulator cells was measured.
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epitope itself was not a prominent peptide product, and quantita-
tion by Edman degradation required that the HPLC fraction con-
taining NP118 (as identified by MALDI-MS) was pooled from
several runs. This analysis revealed that the NP118 nonamer was
produced by constitutive proteasomes to 1.5-fold greater amounts
than by immunoproteasomes. Given that the putative 11- and 12-
mer precursors, but not the NP118 nonamer, meet the criteria for
an efficient transport by TAP transporters (see Discussion), these
in vitro results are consistent with an increased presentation of the
NP118 epitope in cell lines overexpressing LMP2, LMP7, and
MECL-1.
Discussion
The discovery of the genes for the IFN-g-inducible proteasome
subunits LMP2 and LMP7 in the MHC class II locus 10 years ago
had raised great expectations with respect to the function of these
subunits in MHC class I-restricted Ag presentation. The pheno-
types of cell lines or mice deficient for LMP2 and/or LMP7, how-
ever, were subtle and in many systems not apparent. In previous
studies, we and others have tried to characterize the impact of
LMP2 and LMP7 on Ag presentation by overexpressing these sub-
units, thus imitating their induction by IFN-g (13, 48). Despite
strong overexpression of LMP2, there was only little LMP2 pro-
tein incorporated into the 20S proteasome compared with IFN-g-
stimulated cells. The reason for this is now known: the third IFN-
g-inducible exchange of MC14 (or Z) by MECL-1 is required for
incorporation of LMP2 (25, 26), which explains why LMP2 could
only be incorporated efficiently into the proteasome in rare clones
that displayed an endogenous up-regulation of MECL-1 expres-
sion (49). Accordingly, the coexpression of LMP2, LMP7, and
MECL-1 yielded a good incorporation of all three subunits into the
20S proteasome in transfectants similar to immunoproteasomes
from IFN-g-treated cells (Fig. 1). This was the prerequisite to
study their effect on Ag presentation by means of overexpression.
A key finding of our study is that the presentation of the im-
munodominant NP118 epitope by H-2Ld is markedly enhanced in
transfectants overexpressing LMP2, LMP7, and MECL-1. At first
sight, our in vitro results seemed to be at odds with this finding, as
the nonameric NP118 epitope was a minor product in proteasome
digests and was even generated by constitutive proteasomes in
1.5-fold greater amounts compared with immunoproteasomes.
However, the NP118 epitope bears a proline as an anchor residue
FIGURE 7. HPLC profile of fragments gener-
ated by purified 20S proteasomes from a synthetic
25-mer polypeptide in vitro. The 20S proteasomes
were purified from B8 cells or the LMP2/LMP7/
MECL-1 triple transfectant B27 M2. The sequence
of the 25-mer polypeptide spans residues 108–132
of the NP of LCMV-WE and contains the immu-
nodominant epitope NP118 (residues 118–126).
At indicated time points, aliquots were removed
from the peptidolytic reaction and analyzed. The
arrows indicate the retention time of the 9-mer pep-
tide NP118, the 10-mer peptide (residues
117–126), and the peak containing the 11 and 12
mer spanning residues 116–126 and 115–126,
respectively.
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for binding to the H-2Ld class I molecule in position 2. Mouse and
human TAP transporters hardly transport peptides with proline in
position 2 from the cytosol into the ER lumen, suggesting that
N-terminally elongated precursors need to be formed and trans-
ported (3, 2). Interestingly, two potential cytosolic precursors of
this epitope (the 11 or 12 mer in the scheme of Fig. 8) were pro-
duced in 3- and 6-fold greater amounts in vitro if LMP2, LMP7,
and MECL-1 were incorporated into the 20S proteasome. The 11
and 12 mer are good candidates for precursors of the NP118
epitope because they have the appropriate C terminus, which nor-
mally cannot be generated by peptidases other than the proteasome
(5) and because they are not too long to be efficiently transported
by TAP transporters.
The NP118 epitope (shown in Fig. 8) is directly preceded by a
glutamic acid residue at position 117. Proteasomal cleavage events
at the C terminus of glutamic acid have been unanimously shown
to be down-regulated by replacement of the constitutive subunit d
through LMP2 when proteasome activity was measured with help
of fluorogenic peptides (11–14) or polypeptides (36). This finding
would be consistent with our in vitro result that the generation of
the NP118 9 mer, which requires the cleavage C terminal of
Glu117, is generated less efficiently by LMP2-containing immuno-
proteasomes as compared with constitutive proteasomes. The gen-
eration of the 11- and 12-mer precursors, in contrast, may have
been enhanced by suppressing cleavages at Glu117. If the NP118
nonamer cannot be efficiently conveyed by the TAP transporter,
then the suppression of the cleavage after Glu117 would favor the
generation of the required precursors, and thus enhance Ag pre-
sentation as we have observed. The suppression of cleavages C
terminal of glutamic acids may also explain earlier results by Si-
bille et al. (21), who noted that LMP2 was required for the pre-
sentation of two influenza hemagglutinin epitopes, HA11
(FEANGNLI) and HA8 (IEGGWTGMI), both of which contain
glutamic acid residues within their sequence.
Another interesting residue in the NP118 epitope is the proline
in the second position serving as an anchor residue for H-2Ld. A
recent analysis of how the proteasome may process polypeptides
containing proline residues suggested that proline within an
epitope sequence may preserve the epitope from destruction by
proteasome-mediated internal cleavages (50). This proposal would
fit nicely with the fact that proline is an anchor residue for several
human and murine MHC class I molecules. It has been shown by
inhibitor studies (51, 52) and the statistical analysis of proteasomal
cleavage products (53) that it is not only the P1 residue that defines
substrate binding and proteasomal cleavage, but that up to 5 aa to
both sides of the proteolytic site may codetermine whether a cleav-
age occurs or not. While according to extrapolations from the
three-dimensional structure of yeast proteasomes the exchange of
LMP2 for d renders the preference for the P1 residue from acidic
to hydrophobic (54, 52), an obvious modification of the P1 pocket
could not be predicted for the exchanges of LMP7 for MB-1 and
MECL-1 for MC14. It would therefore be interesting to investigate
whether LMP7 and MECL-1 introduce preferences for positions
other than P1 and whether proline could be one of them. Finally,
it is noteworthy that the 11-mer fragment that is produced in 6-fold
excess by immunoproteasomes compared with constitutive protea-
somes is liberated by cleavage C terminal of an arginine residue.
Arginine is a prominent proteasome cleavage site and is used by
several human MHC class I molecules as a C-terminal anchor
residue. Interestingly, the constitutive homologue of MECL-1,
named MC14 in the mouse and PUP1 in yeast, was shown to be in
charge of cleavages C terminal of basic residues (55, 53, 56). It
would therefore be interesting to test whether the incorporation of
human MECL-1 into the proteasome may enhance the cleavages C
terminal of arginine.
New and convincing evidence that the incorporation of LMP2,
MECL-1, and/or LMP7 can determine the fate of an epitope have
been reported while this work was in revision. Sewell et al. (57)
FIGURE 8. Quantitation of selected fragments
produced from the LCMV-NP 25-mer polypeptide by
20S proteasomes purified from B8 cells and B27 M2
cells in vitro. The sequence of the 25- and 9-mer
NP118 as well as putative precursor fragments are
indicated above. The quantitation was performed by
automated Edman degradation of peptide fragments
that were obtained after 48 h of in vitro digest and
fractionation by HPLC, as shown in Fig. 7. Quanti-
tation of the NP118 nonamer by Edman degradation
(bottom) could not be accomplished from the same
single run as the other fragments, but required pool-
ing of the NP118-containing fractions from several
HPLC runs separating in total a 12-fold greater
amount of peptide product.
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reported that an HLA-A0201-restricted epitope from the N termi-
nus of HIV-1 reverse transcriptase was only presented when cells
were expressing LMP7. Also, an epitope from influenza matrix
protein could only be presented on HLA-A0201 when LMP7 was
expressed in the infected cells (58). Sijts et al. showed that an
HLA-Aw68-restricted epitope from hepatitis B virus core Ag
could only be presented under IFN-g stimulation, and in vitro re-
sults suggested that LMP2, LMP7, and MECL-1 were required for
the epitope generation (59). In contrast to these studies, the gen-
eration of several tumor epitopes was recently shown to be abro-
gated by IFN-g treatment of tumor cells, and at least for the RU1
Ag of renal carcinoma the overexpression of LMP2, LMP7, and
MECL-1 was shown to reduce the presentation of an HLA-B51-
restricted RU1 epitope (60). Taken together, it appears that al-
though LMP2, LMP7, and MECL-1 incorporation seems to
slightly increase the total amount of suitable class I ligands (15),
the effect on the single epitope can be either deleterious or bene-
ficial. It is therefore quite important to note whether a given CTL
epitope was characterized in presenting cells that do or do not
express LMP2, LMP7, or MECL-1.
A somewhat surprising finding of this study was the fact that
overexpression of PA28a and PA28b to the same or even higher
degree as obtained with IFN-g stimulation did not alter the pre-
sentation of the NP118 epitope. Previously, we have found that
either the single overexpression of PA28a (34) or the concerted
expression of PA28a and b enhanced the presentation of T cell
epitopes from mouse CMV pp89 protein or the NP of influenza
virus. Mechanistically, the detailed analysis of in vitro digests sug-
gested that PA28 may induce the proteasome to perform concerted
dual cleavages that would liberate fragments of appropriate length
for MHC class I binding (35). It was proposed that PA28 may
achieve these dual cleavages by coordinating the cleavage reac-
tions of two juxtaposed active centers of the proteasome, which
can be spanned by a nonameric peptide in extended conformation.
However, this effect should in theory be of advantage for the gen-
eration of all epitopes. Thus, our results suggest that PA28 func-
tions in a different and more epitope-specific way. Although it has
meanwhile been confirmed by a number of groups that PA28
markedly alters proteasomal cleavage reactions in vitro (13, 35, 36,
50), the principles and mechanisms of PA28 function still need to
be better defined.
IFN-g induces a multitude of genes that affect Ag processing
and also have direct adverse effects on viral replication. It is hence
not easy to decide to which degree the different gene products
contribute to the elimination of LCMV in vivo. The application of
neutralizing Abs to IFN-g in mice showed that this treatment en-
hanced the viral load in the course of the immune response (61)
and that neutralization of IFN-g could prevent elimination of the
virus (62). More recent experiments in gene-targeted mice defi-
cient for IFN-g showed that in the absence of IFN-g, LCMV could
be eliminated after an acute experimental infection, although the
cytolytic activity of LCMV-specific CTLs from these mice was
reduced by a factor of 2–3. Similarly, mice that lacked the IFN-g
receptor were able to clear an acute infection with LCMV, but
virus titers on day 10 postinfection remained 10 times higher in
spleen and lung, but 1,000 and 10,000 times higher in liver and
ovary, respectively (63). Interestingly, the organs with the lowest
titer of LCMV in IFN-gRo/o as compared with wild-type mice
(spleen, lung) were organs of high constitutive expression of
LMP2, LMP7, and MECL-1 (64). Whether LMP2, LMP7, and
MECL-1 contribute to these in vivo effects should now be inves-
tigated in gene-targeted mice deficient for LMP2 or LMP7.
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